Rejuvenate Biomed secures €3.2 million series A round
The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia. The round was led by Vesalius Biocapital III.
Clinical Advisory Board meeting: review clinical strategy
Rejuvenate Biomed held its first Clinical Advisory Board to evaluate the clinical development plan for RJx-01 as a safe therapeutic to treat sarcopenia.
Key research collaboration with Prof. Rafael de Cabo
Rejuvenate Biomed collaborates under a Cooperative Research & Development Agreement (CRADA) with Dr. Rafael de Cabo, MD, PhD, Professor at the NIA`s Translational Gerontology Branch.
Scientific Advisory Board meeting: review preclinical data
Rejuvenate Biomed's SAB concluded that our data do not only provide POP for sarcopenia, but demonstrate multiple opportunities in other muscle- and non-muscle-related disorders.
VLAIO funding (Baekeland mandate)
Rejuvenate Biomed supports Sven Bulterijs in his PhD under guidance of Prof. Bart Braeckman at Ghent University. His work will focus on C. elegans research in the context of aging.